Product Information
ZERVIATE 0.24% EYE DROP is a brand product labeled by Harrow Eye, LLC, priced at $7.3536 per EA under NDC 82667001524. Its NADAC has been published 48 times since Nov 5, 2025.
FDA first approved this application on May 30, 2017.
Strength
2.4 mg/mL
Manufacturer
Harrow Eye, LLCNDC
82667001524
Classification
Brand
Dosage Form
FOR SOLUTION
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
CETIRIZINEApproval Type
New Drug (NDA)
FDA Application
NDA208694FDA Approved
5/30/2017
On Market Since
4/30/2025
Pharmacological Classes
Price Statistics
The NADAC for ZERVIATE 0.24% EYE DROP has been published 48 times since Nov 5, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.3536 per EA |
|---|---|
| All-time high | $7.3572 (Aug 12, 2026) |
| All-time low | $7.3243 (Apr 22, 2026) |
| 52-week high | $7.3572 |
| 52-week low | $7.3243 |
| Median price | $7.3519 |
| Average price | $7.3474 |
| Largest weekly change | +0.3% (Jun 17, 2026) |
| Weeks tracked | 48 |
| Tracking since | Nov 5, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the cetirizine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Harrow Eye, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cetirizine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZERVIATE 0.24% EYE DROP?
The current National Average Drug Acquisition Cost (NADAC) for ZERVIATE 0.24% EYE DROP, manufactured by Harrow Eye, LLC, is $7.3536 per EA (NDC 82667001524), effective Sep 30, 2026.
How has the price of ZERVIATE 0.24% EYE DROP changed over time?
Over the history we have for it, the NADAC for ZERVIATE 0.24% EYE DROP has held within roughly two percent of its current level. It has been tracked across 48 weekly CMS publications since Nov 5, 2025.
What are the highest and lowest recorded NADAC prices for ZERVIATE 0.24% EYE DROP?
Since Nov 5, 2025, the NADAC for ZERVIATE 0.24% EYE DROP has ranged from a low of $7.3243 (Apr 22, 2026) to a high of $7.3572 (Aug 12, 2026), with a median of $7.3519 per EA.
Are there cheaper alternatives to ZERVIATE 0.24% EYE DROP?
No other NADAC-published product currently shares the active ingredient and strength of ZERVIATE 0.24% EYE DROP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZERVIATE 0.24% EYE DROP?
ZERVIATE 0.24% EYE DROP (NDC 82667001524) is labeled by Harrow Eye, LLC, and CMS classifies it as a brand product.